Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients소아 환자에서 COVID-19 치료를 위한 단일클론항체 요법의 안전성 및 내약성Article Published on 2021-12-012022-09-11 Journal: The Pediatric Infectious Disease Journal [Category] SARS, 진단, 치료제, [키워드] Adults COVID-19 effective Efficacy Mild-to-moderate monoclonal antibody monoclonal antibody therapy monoclonal antibody treatment Patient Pediatric patient Pediatric patients progression Retrospective study Safe Safety severe disease therapy Treatment [DOI] 10.1097/INF.0000000000003263 PMC 바로가기 [Article Type] Article
Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surgeSARS-CoV-2 B1.617.2(델타) 급증 중 획기적인 COVID-19 및 카시리비맙-임데비맙 치료Article Published on 2021-12-012022-09-11 Journal: Journal of Clinical Virology [Category] MERS, SARS, 변종, 진단, 치료법, [키워드] 95% confidence interval Casirivimab Clinical outcome cohorts Comorbidities COVID-19 COVID-19 case Delta delta variant eligible enrolled high-risk patient Hospitalization Imdevimab individuals majority monoclonal antibody monoclonal antibody treatment occurred outcomes Patient patients with COVID-19 Ratio receive SARS-CoV-2 significantly lower study period treated Treatment untreated patients vaccinated individual vaccinated individuals vaccination [DOI] 10.1016/j.jcv.2021.105026 PMC 바로가기 [Article Type] Article
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 20192019년 경증에서 중등도의 코로나바이러스 질환 고위험 환자 중 밤라니비맙과 카시리비맙-임데비맙의 실제 임상 결과Observational Study Published on 2021-10-282022-09-12 Journal: The Journal of Infectious Diseases [Category] MERS, SARS, 임상, 진단, [키워드] adjusted Adult patient age bamlanivimab cardiovascular diseases Casirivimab chronic clinical clinical outcomes Comorbidities Comorbidity coronavirus disease COVID-19 Factor female groups hazard ratio high-risk patient High-risk patients Hospitalization identify immunocompromised status kidney likelihood Mild moderate monoclonal antibody monoclonal antibody treatment multiple comorbidities no significant difference outcome outcomes Patient selected the median therapy Treatment [DOI] 10.1093/infdis/jiab377 PMC 바로가기 [Article Type] Observational Study
Administration of Monoclonal Antibody for COVID-19 in Patient Homes환자 가정에서 COVID-19에 대한 단클론항체 투여Research Published on 2021-10-142022-09-12 Journal: JAMA Network Open [Category] MERS, SARS, 진단, [키워드] cohort study COVID-19 home monoclonal antibody treatment Monoclonal antibody treatments outcome Patient positive patients Program [DOI] 10.1001/jamanetworkopen.2021.29388 PMC 바로가기 [Article Type] Research
Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19COVID-19에 대한 단일 클론 항체 치료를 받았거나 받지 않은 고위험 아메리카 원주민 환자의 결과 비교Comparative Study Published on 2021-09-212022-09-12 Journal: JAMA Network Open [Category] SARS, 진단, [키워드] COVID-19 monoclonal antibody monoclonal antibody treatment Native outcome Patient Quality improvement receive [DOI] 10.1001/jamanetworkopen.2021.25866 PMC 바로가기 [Article Type] Comparative Study
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline코로나바이러스 질환 2019(COVID-19)로 입원한 성인 관리: 유럽 호흡기 학회 생활 지침Practice Guideline Published on 2021-04-152022-09-11 Journal: The European Respiratory Journal [Category] Fulltext, MERS, meta-analysis, [키워드] anticoagulation approach Azithromycin Care Chinese Colchicine Continuous Positive Airway Pressure coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 European Evidence high mortality rate High-flow nasal oxygen hospitalised Hospitalised patients Hydroxychloroquine hypoxaemic respiratory failure IMPROVE initial interleukin Intervention Invasive mechanical ventilation invasive ventilation literature review Lopinavir Lopinavir-ritonavir management Meta-analysis monoclonal antibody treatment noninvasive respiratory Optimising outcome outcomes oxygen Patient performed pharmacological PICO positive airway pressure receptor receptor antagonist recommendation recommendations Remdesivir requiring supplemental oxygen Research respiratory Respiratory failure Ritonavir SARS-COV-2 infection Society strength supplemental oxygen supplementary oxygen Support systemic corticosteroid systemic corticosteroids Task Force use of hydroxychloroquine ventilatory support was used were used [DOI] 10.1183/13993003.00048-2021 PMC 바로가기 [Article Type] Practice Guideline
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19경증-중등도 COVID-19 고위험군 환자의 단클론항체 치료 동의 결정에 대한 사회적, 문화적 요인의 영향Article Published on 2021-01-012022-09-12 Journal: Journal of primary care & community health [Category] MERS, 진단, [키워드] age anti-spike monoclonal antibody bamlanivimab Casirivimab chose Clinical outcome Comorbidities confidence Consent coronavirus covid_19 COVID-19 COVID-19 diagnosis Cultural decision declined effort Endpoint English enrolled Factor Gender high risk Hospitalization identify Imdevimab impacted influence interval lack Mayo Clinic monoclonal monoclonal antibodies monoclonal antibody monoclonal antibody treatment offer offered Patient patient outcomes populations primary endpoint public health Rate Ratio reduce retrospective cohort study sars_cov-2. secondary Support Therapies therapy Treatment white [DOI] 10.1177/21501327211019282 PMC 바로가기 [Article Type] Article